Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744898 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
A Phase 2 study of Endometrial Cancer, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT02744898 is a Phase 2 study of Endometrial Cancer that has completed, run by NYU Langone Health. The registered enrollment target is 23 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02744898, a Phase 2 study of Endometrial Cancer, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety of treatment with carboplatin and Abraxane in this patient population and determine the nature and degree of toxicities following treatment. The single stage open label Phase II feasibility study is designed to estimate the proportion of patients who can tolerate the proposed regimen for 6 cycles with no more than two dose level reductions.
Conditions Studied
Interventions
- DRUG Abraxane
- DRUG Carboplatin AUC
Study Locations (1)
New York
- NYU Perlmutter Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-07 |
| Est. Completion | 2020-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02744898
The ClinicalTrials.gov registry entry for NCT02744898 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (96% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Abraxane is the first listed.
NCT02744898 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02744898 about?
NCT02744898 is a clinical study titled "A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus". The purpose of this study is to evaluate the safety of treatment with carboplatin and Abraxane in this patient population and determine the nature and degree of toxicities following treatment. The single stage open label Phase II feasibility study is designed to estimate the proportion of patients w...
What is the current status of trial NCT02744898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2016-07. Estimated completion is 2020-03-01.
What conditions does trial NCT02744898 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT02744898?
The interventions under investigation include: Abraxane (DRUG), Carboplatin AUC (DRUG).
Who is sponsoring clinical trial NCT02744898?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02744898 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.